The Dow Jones Industrial Average (^DJI) was down 821.91 (-1.66%) points today, as the index retreated to 48,804.06. While Dow Futures (YM=F) was up 126.00 (+0.26%), the spot market struggled under the weight of significant losses in the technology and financial sectors. The dominant narrative was a sharp correction in enterprise tech sentiment following a major decline in IBM (IBM), coupled with renewed fears regarding consumer credit health that battered payment processors and major banks.The primary catal ...

Group 1 - Johnson & Johnson is preparing for a potential sale of its orthopedics unit, DePuy Synthes, as part of its plan to separate the business, targeting completion within 18 to 24 months [1] - The company acquired DePuy Synthes in 2011 for $21.3 billion and aims to enhance strategic and operational focus through this separation [1] - Bank of America analysts believe that the exit makes sense and that DePuy Synthes could benefit from improved focus and competitiveness [3] Group 2 - The unit is estimated to be worth about $20 billion, or $28 billion including debt, with interest from buyout firms and potential strategic medical device players [3][5] - Johnson & Johnson is preparing financial materials for meetings with potential buyers in the coming weeks, with several large private equity firms considering joint bids [4] - DePuy Synthes generated $9.3 billion in annual sales, producing hip and knee replacement devices, which may attract further interest [5] Group 3 - Johnson & Johnson reported a fourth-quarter 2025 adjusted earnings of $2.46 per share, a 20.6% increase year over year, surpassing the consensus estimate of $2.44 [6] - The company expects 2026 sales to be between $99.50 billion and $100.5 billion, compared to the consensus of $98.89 billion [6]

The Dow Jones Industrial Average (^DJI) was down 821.91 (-1.66%) points today, closing at 48,804.06, while Dow Futures (YM=F) fell 857.00 (-1.73%) to 48,817.00. The main narrative driving the market was a sudden 15% blanket tariff announcement, which reignited trade war fears and global economic uncertainty. This policy shift, combined with hawkish Federal Reserve commentary suggesting a "coin flip" for future rate cuts, triggered a massive rotation out of cyclical and growth sectors into defensive assets.F ...

Transaction expected to be accretive to earnings per share from 2028 onwards.Deal provides full control of anito-cel, an investigational CAR-T therapy for multiple myeloma.Gilead Moves Into CAR-T Oncology With Arcellx AcquisitionGilead Sciences just made a big move, announcing a $7.8 billion deal to buy Arcellx. It’s their biggest acquisition since 2020, signaling they’re serious about moving beyond just HIV and liver disease treatments.Arcellx shares shot up right after the news. Gilead’s offering $115 per ...

The Dow Jones Industrial Average (^DJI) was down 798.40 (-1.61%) points today, currently sitting at 48,827.57. Similarly, Dow Futures (YM=F) was down 742.00 (-1.49%) points. The primary narrative driving this sharp decline was a significant "risk-off" rotation triggered by renewed concerns over stubborn inflation data and a potential hawkish shift in monetary policy. This sentiment disproportionately affected the financial and technology sectors, as investors moved capital away from growth-oriented and cred ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

The Dow Jones Industrial Average (^DJI) was down 715.91 (-1.44%) points today, reaching 48,910.06, while Dow Futures (YM=F) was down 740.00 (-1.49%) points. The primary narrative driving the market lower is a sharp retreat in the financial and technology sectors, sparked by a hawkish shift in monetary policy expectations and rising concerns over consumer credit health. Investors are rotating out of cyclical names in favor of defensive havens as economic uncertainty regarding interest rate trajectories for t ...

Skip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivBayer files lawsuit against Johnson & Johnson, Janssen BiotechFebruary 23, 20263:43 PM UTCUpdated agoBy ReutersThe 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical... Purchase Licensing Rights, opens new tab Read moreCompaniesBayer AGJanssen Biotech IncJohnson ...

Core Insights - Johnson & Johnson (JNJ) and AbbVie (ABBV) are prominent pharmaceutical companies with strong positions in immunology, oncology, and neuroscience, alongside J&J's extensive medical devices business [1] - Both companies are facing patent challenges, necessitating effective pipeline execution and business development for sustained growth [2] Company Overview Johnson & Johnson (JNJ) - JNJ's diversified business model includes pharmaceuticals and medical devices, with over 275 subsidiaries and 28 products generating over $1 billion in annual sales [4] - The Innovative Medicine unit showed a 4.1% organic sales growth in 2025, driven by key drugs like Darzalex and new products [5] - JNJ's MedTech business saw a 4.3% organic sales increase in 2025, supported by acquisitions and improvements in various segments [6] - Significant R&D investments exceeding $32 billion in 2025, with new product approvals expected to drive future growth [7] - JNJ anticipates that 10 new products could achieve peak sales of $5 billion each [8] AbbVie (ABBV) - AbbVie successfully transitioned from the loss of exclusivity (LOE) of Humira by launching new immunology drugs, Skyrizi and Rinvoq, which contributed to a combined sales growth of over 40% in 2025 [9][10] - The neuroscience portfolio also saw a nearly 20% sales increase, driven by products like Botox and Vraylar [12] - AbbVie has invested over $5 billion in acquisitions to enhance its early-stage pipeline, particularly in immunology [13] - The aesthetics segment faced challenges, with global sales declining by 5.9% in 2025 [14] Financial Performance - JNJ's stock rose 48% in the past year, while AbbVie's stock increased by 10.2%, both outperforming the industry average of 12.1% [20] - The Zacks Consensus Estimate for JNJ's 2026 sales and EPS indicates a year-over-year increase of 6.5% and 7.0%, respectively [15] - AbbVie's 2026 sales and EPS estimates imply a year-over-year increase of 9.4% and 8.74%, respectively [17] Valuation and Yield - AbbVie appears more attractive from a valuation perspective, trading at a forward P/E ratio of 15.25 compared to JNJ's 20.79 [20] - AbbVie offers a higher dividend yield of approximately 3.1%, compared to JNJ's 2.1% [23] Future Outlook - AbbVie expects high single-digit revenue growth through 2029, driven by Skyrizi and Rinvoq, with no significant LOE events anticipated [27] - JNJ aims for approximately $100 billion in revenues in 2026, with expectations of sales growth across both segments [28] - Both companies are positioned for continued growth, with JNJ showing a slight edge in stock performance and analyst estimates [29]

Core Insights - The European Commission has approved subcutaneous (SC) amivantamab, allowing for administration in minutes rather than hours, with efficacy and safety consistent with intravenous (IV) amivantamab [1][2][3] - SC amivantamab is now authorized for all previously approved IV indications, including every-four-week (Q4W) and every-three-week (Q3W) dosing regimens for advanced non-small cell lung cancer (NSCLC) [1][2][3][4] - The new dosing options aim to reduce administration-related reactions and improve patient convenience [1][2][3][4] Company Developments - Johnson & Johnson announced the approval of SC amivantamab, which is expected to enhance the treatment experience for patients with EGFR-mutated NSCLC [1][2][3] - The approval is part of Johnson & Johnson's commitment to improving patient care and treatment flexibility [1][2][3] Clinical Study Results - The approval is supported by Phase 2 PALOMA-2 and Phase 1 PALOMA studies, which demonstrated that SC amivantamab has a response rate and safety profile similar to IV amivantamab, but with significantly fewer administration-related reactions [1][2][3][4] - Administration time for SC amivantamab is approximately five minutes, compared to five hours for the first IV infusion [1][2][3][4] Treatment Context - Amivantamab is a bispecific antibody targeting EGFR and MET mutations, which are prevalent in NSCLC [3][4] - The approval of SC amivantamab aligns with the growing need for more efficient treatment options in the context of lung cancer, which is the leading cause of cancer-related deaths in Europe [6][7]